Patents Assigned to Genzyme Transgenics Corporation
-
Publication number: 20040006776Abstract: A method for the production of monoclonal antibodies in mammal's milk, through the creation of transgenic animals that selectively express foreign antibody genes in mammary epithelial cells.Type: ApplicationFiled: January 23, 1998Publication date: January 8, 2004Applicant: Genzyme Transgenics CorporationInventors: HARRY MEADE, PAUL DITULLIO, DANIEL POLLOCK
-
Patent number: 6593463Abstract: The invention provides modified recombinant nucleic acid sequences (preferably DNA) and methods for increasing the mRNA levels and protein expression of malarial surface protein MSP-1 which is known to be difficult to express in cell culture systems, mammalian cell culture systems, or in transgenic animals. The preferred protein candidates for expression using the recombinant techniques of the invention are MSP-1 proteins expressed from DNA coding sequences comprising reduced overall AT content or AT rich regions and/or mRNA instability motifs and/or rare codons relative to the native MSP-1 gene.Type: GrantFiled: October 20, 1998Date of Patent: July 15, 2003Assignee: Genzyme Transgenics CorporationInventors: Li How Chen, Harry Meade
-
Patent number: 6580017Abstract: The invention features methods of producing a mammal, e.g., a cloned or transgenic mammal. The method includes maintaining a reconstructed embryo in culture until the embryo is in the 2 to 8 cell stage of embryogenesis, transferring the embryo at the 2 to 8 cell stage into a recipient mammal, and allowing the embryo to develop into a mammal.Type: GrantFiled: April 23, 1999Date of Patent: June 17, 2003Assignee: Genzyme Transgenics CorporationInventors: Yann Echelard, Esmail Behbodi, William Gavin, David Melican
-
Publication number: 20030096974Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.Type: ApplicationFiled: July 2, 2002Publication date: May 22, 2003Applicant: Genzyme Transgenics Corporation, a Massachusetts corporationInventors: Paul Ditullio, Harry M. Meade, Edward S. Cole
-
Patent number: 6548653Abstract: Erythropoietin analog-human serum albumin (EPOa-hSA) fusion protein and methods of making and using the fusion protein.Type: GrantFiled: June 15, 1999Date of Patent: April 15, 2003Assignee: Genzyme Transgenics CorporationInventors: Michael Young, Harry Meade, Ian Krane
-
Patent number: 6545198Abstract: Transgenically produced prolactin and methods of making and using transgenically produced prolactin.Type: GrantFiled: January 24, 2000Date of Patent: April 8, 2003Assignee: Genzyme Transgenics CorporationInventors: Yann Echelard, Brian Wilburn
-
Patent number: 6528699Abstract: The invention provides a method of making and secreting a non-secreted protein. The method includes expressing the protein from a nucleic acid construct which includes: (a) a mammary epithelial specific promoter; (b) a milk protein specific signal sequence which can direct the secretion of a protein; (c) optionally, a sequence which encodes a sufficient portion of the amino terminal coding region of a secreted protein to allow secretion in the milk of a transgenic mammal, of the non-secreted protein; and (d) a sequence which encodes a non-secreted protein, wherein elements (a), (b), optionally (c), and (d) are preferably operatively linked in the order recited. Both glutamic acid decarboxylase (GAD) and myelin basic protein (MBP), which are cytoplasmic proteins, have been produced by the methods of the present invention. The invention also provides methods for treating diabetes and multiple sclerosis using proteins produced by the methods of the present invention.Type: GrantFiled: February 24, 1998Date of Patent: March 4, 2003Assignee: Genzyme Transgenics CorporationInventors: Harry Meade, Li-How Chen, Paul DiTullio
-
Publication number: 20020155998Abstract: Erythropoietin analog-human serum albumin (EPOa-hSA) fusion protein and methods of making and using the fusion protein.Type: ApplicationFiled: February 20, 2002Publication date: October 24, 2002Applicant: Genzyme Transgenics Corporation, a Massachusetts corporationInventors: Michael Young, Harry Meade, Ian Krane
-
Publication number: 20020144299Abstract: The invention provides modified recombinant nucleic acid sequences (preferably DNA) and methods for increasing the mRNA levels and protein expression of malarial surface protein MSP-1 which is known to be difficult to express in cell culture systems, mammalian cell culture systems, or in transgenic animals. The preferred protein candidates for expression using the recombinant techniques of the invention are MSP-1 proteins expressed from DNA coding sequences comprising reduced overall AT content or AT rich regions and/or mRNA instability motifs and/or rare codons relative to the native MSP-1 gene.Type: ApplicationFiled: February 20, 2002Publication date: October 3, 2002Applicant: Genzyme Transgenics Corporation, a Massachusetts corporationInventors: Li How Chen, Harry M. Meade
-
Patent number: 6268487Abstract: A method of separating a soluble milk component from milk is disclosed. The method involves the use of tangential flow filtration across a membrane to form a retentate and a permeate, combining the permeate with the original milk sample, and repeating this procedure until the milk has been sufficiently purified. Preferably, the milk is combined with a chelating agent, such as EDTA, to improve the purification efficiency. This procedure is advantageously employed with milk from transgenic animals which have been genetically altered to express exogenous proteins, such as therapeutic proteins, in their milk.Type: GrantFiled: May 13, 1996Date of Patent: July 31, 2001Assignee: Genzyme Transgenics CorporationInventors: Joseph P. Kutzko, Michael L. Hayes, Lee T. Sherman
-
Patent number: 6210736Abstract: Transgenically produced prolactin and methods of making and using transgenically produced prolactin are disclosed.Type: GrantFiled: June 15, 1998Date of Patent: April 3, 2001Assignee: Genzyme Transgenics CorporationInventors: Yann Echelard, Brian Wilburn
-
Patent number: 6073818Abstract: Apparatus and methods for accurate delivery of relatively small quantities of powdered solid materials. Preferred apparatus comprise: a primary chamber having a lateral surface extending between a first open end and a second open end; a rotating member that is positioned within the primary chamber and extends from a first position within the primary chamber to a second position within the primary chamber; a motor coupled with the rotating member and adapted to effect rotation thereof; a feed chamber having a lateral surface extending between a first open end and a second open end; and an air flow chamber coupled with the primary chamber and having a lateral surface extending between a first open end and a second open end.Type: GrantFiled: June 19, 1998Date of Patent: June 13, 2000Assignee: Genzyme Transgenics CorporationInventors: Simon J. Rothenberg, Richard Joel Hershman, Brian Alan Wong
-
Patent number: 5896829Abstract: Animal exposure chambers are provided which have a radial configuration about an axis of air flow and tapered ports to more comfortably accommodate the animals during exposure.Type: GrantFiled: October 8, 1997Date of Patent: April 27, 1999Assignee: Genzyme Transgenics CorporationInventors: Simon J. Rothenberg, George Dearlove, John Barnett, Daniel Dewees, William Ehrhart
-
Patent number: 5849992Abstract: A method for the production of monoclonal antibodies in mammal's milk through the creation of transgenic animals that selectively express foreign antibody genes in mammary epithelial cells.Type: GrantFiled: March 27, 1995Date of Patent: December 15, 1998Assignee: Genzyme Transgenics CorporationInventors: Harry Meade, Paul Ditullio, Daniel Pollock
-
Patent number: 5843705Abstract: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GaINAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.Type: GrantFiled: February 21, 1995Date of Patent: December 1, 1998Assignee: Genzyme Transgenic CorporationInventors: Paul DiTullio, Harry Meade, Edward S. Cole
-
Patent number: 5756687Abstract: Methods of isolating components of interest from a milk sample are described. The methods include a step wherein the solubility of at least a portion of the total milk protein is stabilized in such a manner as to allow isolation of the component of interest without significant loss in yield. Kits for stabilizing the solubility of at least a portion of the total milk protein of the milk sample containing the component of interest also are described.Type: GrantFiled: January 23, 1995Date of Patent: May 26, 1998Assignee: Genzyme Transgenics CorporationInventors: Julie S. Denman, Edward S. Cole